The sales value forecast for the systemic hormonal preparations (excluding sex hormones and insulins) in Spain remains constant at 1.9% of total sales from 2024 to 2028. The data suggests a steady market with no annual variation over the five-year forecast period.
Year-on-year variations: []. The Compound Annual Growth Rate (CAGR) over the past five years is 0%, indicating no average annual change.
Considering the stable forecast, it will be essential to monitor any shifts in the regulatory environment, advancements in hormonal therapies, and any emerging competition from alternative treatments which may impact future sales trends.
